Synthetic biology specialist Synlogic will start phase 3 testing of a drug for rare metabolic disorder phenylketonuria (PKU) next year, after reporting solid proof-of-concept data.

PTC Therapeutics (PTCT) is advancing 8% after investment bank Cantor Fitzgerald’ hiked its price target on the drug maker’s ...

NEW YORK — MRC Holland said on Thursday that its blood-based assay for Temple, Kagami-Ogata, and Russell-Silver syndromes has received certification under Europe's In Vitro Diagnostic Regulation (IVDR ...

PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest ...

Introduction to Newborn Screening InstrumentsNewborn screening is a critical medical process that involves testing newborns for certain genetic, metabolic, and congenital conditions. The objective is ...

Kiesel was a political commentator on KOSU’s weekly radio program and podcast This Week in Oklahoma Politics for 13 years.

After hours: February 4 at 4:25:05 PM EST Loading Chart for AGIO ...

PTC Therapeutics, Inc. (NASDAQ:PTCT), a biopharmaceutical company focused on developing and commercializing novel medicines for rare disorders, finds itself at a critical juncture. With a promising ...

Genetic alterations may help mosquitoes adjust to climate change, shifting the distribution of mosquito-borne disease in a warming planet.